Abstract

BackgroundHypertension has a significant relevance as a cardiovascular risk factor. A consistent increase on world’s Metabolic Syndrome (MetS) incidence has been associated with an epidemic cardiovascular risk in different populations. Dislipidemia plays a major role determining the epidemic CV burden attributed to MetS. Apolipoprotein E (ApoE) is involved on cholesterol and triglycerides metabolism regulation. Once ApoE polymorphism may influence lipid metabolism, it is possible that it brings on individual susceptibility consequences for the development of MetS and cardiovascular risk. The objective of the study is to measure the discriminatory power of ApoE polymorphism in determining cardiovascular risk stratification based on the presence MetS in a cohort of hypertensive patients.MethodsIt was enrolled 383 patients, divided in two groups, classified by MetS presence (IDF criteria): Group 1: 266 patients with MetS (MetS +) and Group 2: 117 patients without Mets (MetS -). Patient’s data were collected by clinical evaluation, physical exam, file reviews and laboratory testing. Polymorphic ApoE analysis was performed by PCR amplification. Groups were compared on clinical and laboratory characteristics as well as allele and genotype distribution towards ApoE polymorphism. Mets CVD prevalence was analysed according to E4 allele prevalence.ResultsThe results evidenced 184 men (48%), 63,7% whites, 45,1% diabetics and 11,7% of patients were smokers. Mean age was 64,0 ± 12,0 years. When genotypic distribution was analyzed, E3/3 genotype and E3 allele frequencies were more prevalent. Among patients with MetS, we observed an independent association between CVD prevalence and E4 allele frequency (OR 2.42 (1.17- 5.0, p < 0,05)). On the opposite direction, in those without MetS, there was lesser CVD burden in E4 allele carriers (OR 0,14 (0,02-0,75)). These associations remained significant even after confounding factor corrections.ConclusionsThe results presented demonstrate that the association between ApoE gene and CVD may be modulated by the presence of MetS, with an increased CV burden observed among E4 allele carriers with the syndrome. On the opposite way, E4 allele carriers without visceral obesity had lesser prevalence of CVD.

Highlights

  • Hypertension has a significant relevance as a cardiovascular risk factor

  • Apolipoprotein E (ApoE) is the main constituent of tg-rich lipoprotein and genetic polymorphic variations of this protein has been associated with cardiovascular disease (CVD) occurrence

  • Metabolic Syndrome (MetS) (+) group showed higher prevalence of men and, as expected, weight, Body mass index (BMI), waist, C-reactive protein (CRP), dislipidemia and CVD prevalence were higher in this group when comparing with Metabolic syndrome (Mets) (−) group

Read more

Summary

Introduction

Hypertension has a significant relevance as a cardiovascular risk factor. A consistent increase on world’s Metabolic Syndrome (MetS) incidence has been associated with an epidemic cardiovascular risk in different populations. Hypertension has a worldwide prevalence estimated in 1 billion of people, an attributable mortality of 7,1 million of deaths per year and a significant relevance as a cardiovascular risk factor. A significant portion of CVD in MetS may be explained by the presence of well-known risk factors, a significant proportion remains unexplained possibly due to individual genetic variability. Among those individuals with MetS, dislipidemia and its consequences (coronary artery disease, stroke and others) are attributed to a conjunct and integrative action between genetic and environmental factors. Identification of genetic markers has clinical relevance in this context, as for risk prediction as for adoption of therapeutic maneuvers

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call